[1]Li H,Min D,Zhao H,et al.The prognostic role of Ezrin immunoexpression in osteosarcoma:A Meta-analysis of published data［J］.PLoS One,2013,8（6):e64513.
[2]Haddox CL,Han G.Osteosarcoma in pediatric patients and young adults:A single institution retrospective review of presentation,therapy,and outcome［J］.Sarcoma,2014,2014:402509.
[3]Wafa H,Grimer RJ.Surgical options and outcomes in bone sarcoma［J］.Expert Rev Anticancer Ther,2006,6:239-248.
[4]Goricar K,Kovac V,Jazbec J,et al.Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma［J］.Pharmacogenet Genomics,2014,24:514-521.
[5]Yang J,Yang D,Sun Y,et al.Genetic amplification of the vascular endothelial growth factor（VEGF) pathway genes,including VEGFA,in human osteosarcoma［J］.Cancer,2011,117(21):4925-4938.
[6]Andersen S,Donnem T,Al-Shibli K,et al.Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma:VEGF-A impact is strongly associated with Ang-2［J］.PLoS One,2011,6:e19773.
[7]Zhang G,Bai R,Zhang T,et al.Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma［J］.Genet Mol Res,2015,14（3):8283-8289.
[8]Liu JQ,Bai X,Duan DC,et al.Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients［J］.Oncol Lett,2015,10（3):1481-1486.
[9]Wang Z,Wen P,Luo X,et al.Association of the vascular endothelial growth factor（VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population［J］.Tumour Biol,2015,35（4):3605-3610.
[10]Hu GL,Ma G,Ming JH.Impact of common SNPs in VEGF gene on the susceptibility of osteosarcoma［J］.Genet Mol Res,2015,14（4):14561-14566.
[11]Ti Z,Bai R,Zhai Z,et al.Single nucleotide polymorphisms in VEGF gene are associated with an increased risk of osteosarcoma［J］.Int J Clin Exp Pathol,2014,7（11):8143-8149.
[12]Li LZ,Lin W,Lei S,et al.Investigation on the role of VEGF gene polymorphisms in the risk of osteosarcoma［J］.Pak J Med Sci,2015,31（2):364-368.
[13]Vairaktaris E,Yapijakis C,Serefoglou Z,et al.The interleukin-8（-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma［J］.Eur J Surg Oncol,2007,33（4):504-507.
[14]Cui Y,Zhu JJ,Ma CB,et al.Interleukin 10 gene-1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population［J］.Tumour Biol,2016,37（4):4517-4522.
[15]AlSuhaibani ES,Kizilbash NA,Malik S,et al.Polymorphisms in promoter regions of IL-6 and IL-10 genes in breast cancer:A case-control study［J］.Genet Mol Res,2016,15(1):56.
[16]Horvat V,Mandic S,Marczi S,et al.Association of IL-1 beta and IL-10 polymorphisms with prostate cancer risk and grade of disease in Eastern Croatian population［J］.Coll Antropol,2015,39（2):393-400.
[17]Mukaida N,Shiroo M,Matsushima K.Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8［J］.J Immunol,1989,143:1366-1371.
[18]Beck A,Pazolt D,Grabenbauer GG,et al.Expression of cytokine and chemokine genes in Epstein-Barr virus associated nasopharyngeal carcinoma:Comparison with Hodgkin's disease［J］.J Pathol,2001,194:145.
[19]Chen Y,Yang Y,Liu S,et al.Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population:A case-control study［J］.Tumour Biol,2016,37（5):6191-6196.
[20]Kumar S,Kumari N,Mittal RD,et al.Association between pro-(IL-8) and anti-inflammatory（IL-10) cytokine variants and their serum levels and Hp-related gastric carcinogenesis in northern India［J］.Meta Gene,2015,6:9-16.
[21]Singh PK,Chandra G,Bogra J,et al.Association of genetic polymorphism in the interleukin-8 gene with risk of oral cancer and its correlation with pain［J］.Biochem Genet,2016,54（1):95-106.
[22]Dinarello CA.Biologic basis for interleukin-1 in disease［J］.Blood,1996,87:2095-2147.
[23]Heresbach D,Alizadeh M,Dabadie A,et al.Significance of interleukin-1 beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases［J］.Am J Gastroenterol,1997,92:1164-1169.
[24]He Y,Liang X,Meng C,et al.Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk［J］.Int Orthop,2014,38（8):1671-1676.
[25]Wang JL,Nong LG,Wei YS,et al.Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk［J］.DNA Cell Biol,2013,32（10):605-610.
[26]Tang YJ,Wang JL,Nong LG,et al.Associations of IL-27 polymorphisms and serum IL-27p28 levels with osteosarcoma risk［J］.Medicine（Baltimore),2014,93（10):e56.
[27]Esteller M,Sanchez-Cespedes M,Rosell R,et al.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients［J］.Cancer Res,1999,59（1):67-70.
[28]Pellatt AJ,Wolff RK,Lundgreen A,et al.Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study［J］.Int J Mol Epidemiol Genet,2012,3:184-194.
[29]Dong YZ,Huang YX,Lu T.Single nucleotide polymorphism in the RECQL5 gene increased osteosarcoma susceptibility in a Chinese Han population［J］.Genet Mol Res,2015,14（1):1899-1902.
[30]Zhi LQ,Ma W,Zhang H,et al.Association of RECQL5 gene polymorphisms and osteosarcoma in a Chinese Han population［J］.Tumour Biol,2014,35（4):3255-3259.
[31]Jin G,Wang M,Chen W,et al.Single nucleotide polymorphisms of nucleotide excision repair and homologous recombination repair pathways and their role in the risk of osteosarcoma［J］.Pak J Med Sci,2015,31（2):269-273.
[32]Ma X,Zhang Y,Sun TS,et al.Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma［J］.Genet Mol Res,2016,15（1):gmr15017302.
[33]Wang Z.Association of polymorphism of ARHGAP35 gene with genetic susceptibility and clinical prognosis of osteosarcoma［D］.Nanning:Guangxi Medical University,2014.［王哲.ARHGAP35基因多态性与骨肉瘤的遗传易感性及临床预后的相关性研究［D］.南宁：广西医科大学,2014.］
[34]Lu XF， Yang WL， Wan ZH， et al．Glutathione S-transferase polymorphisms and bone tumor risk in China［J］．Asian Pac J Cancer Prev,2011,12(12):3357-3360．
[35]Li XX,Xiao Y.Meta analysis of glutathione S-transferase M1,T1 gene polymorphism and osteosarcoma susceptibility ［J］.Shandong Medical J,2013,53(36):11-13.［李夏西,肖颖.谷胱甘肽S-转移酶M1、T1基因多态性与骨肉瘤易感性的Meta分析［J］.山东医药,2013,53(36):11-13.］
[36]Courtney KD,Corcoran RB,Engelman JA.The PI3K pathway as drug target in human cancer［J］.J Clin Oncol,2010,28:1075-1083.
[37]He ML,Wu Y,Zhao JM,et al.PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population［J］.Asian Pac J Cancer Prev,2013,14（9):5117-5122.
[38]Teft WA,Kirchhof MG,Madrenas J.A molecular perspective of CTLA-4 function［J］.Annu Rev Immunol,2006,24:65-97.
[39]Contardi E,Palmisano GL,Tazzari PL,et al.CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction［J］.Int J Cancer,2005,117(4):538-550.
[40]He J,Wang J,Wang D,et al.Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population［J］.Endocrine,2014,45（2):325-330.
[41]Tsuji T.Physiological and pathological roles of alpha3 beta1 integrin［J］.J Membr Biol,2004,200(3):115-132.
[42]Yang W,He M,Zhao J,et al.Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma［J］.Med Oncol,2014,31（2):826.
[43]Zhang Shiquan,Xiao Deming,Zhu Yuhua,et al.Expression and clinical significance of p53 gene in osteosarcoma［J］.Modern Oncology,2011,19(01):145-146.［张世权,肖德明,朱玉华,等.p53基因在骨肉瘤中的表达及其临床意义［J］.现代肿瘤医学,2011,19(01):145-146.］
[44]Liu Y,Teng Z,Wang Y,et al.Prognostic significance of survivin expression in osteosarcoma patients:A Meta-analysis［J］.Med Sci Monit,2015,21:28877-28885.
[45]Hu D,Huang JW,Hu SP,et al.Expression and correlation of p53,p63 and p73 protein in osteosarcoma［J］.Chin J Bone Tumor and Bone Disease,2004,03(01):47-50.［胡丹,黄健文,胡世平,等.p53、p63、p73蛋白在骨肉瘤中的表达及相关性研究［J］.中国骨肿瘤骨病,2004,03(01):47-50.］